Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment uncertainty clouds the 2025 view, but at $12 per share, 10x Genomics has “quite a few challenges baked into the stock” price, says the analyst. However, it is “fair to assume that operating environment clarity will be needed for most,” the analyst added in a post-earnings and guidance note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target lowered to $12 from $14 at JPMorgan
- 10x Genomics price target lowered to $20 from $23 at Citi
- 10x Genomics price target lowered to $18 from $20 at Canaccord
- 10x Genomics downgraded to Market Perform from Outperform at Leerink
- 10x Genomics Reports 2024 Earnings and 2025 Outlook